Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escape.

Overview

abstract

BACKGROUND: The heritability of urinary tract cancer (UTC) remains unexplained by known pathogenic germline variants, and the influence of germline variants on treatment response to immune checkpoint inhibition (ICI) has yet to be fully elucidated. METHODS: In this case-control study, we performed a germline whole-exome sequencing of 810 UTC patients from the Oncology Research Information Exchange Network. A rare-variant burden test was conducted on the 810 patients and 2354 healthy controls from the Centre d'Etudes du Polymorphisme Humain families, the University of Utah Heritage 1000 Projects, and the 1000 Genomes Project, stratified into discovery and confirmation sets. We used a gene set-based rare-variant association test (GSRVAT) with near-match confirmation, testing for the association of pathways with UTC susceptibility and accounting for multiple testing. We then studied the impact of the identified pathways on tumor biology and clinical course among the 810 cases by analyzing their tumor exomes, transcriptomes, and clinical features. RESULTS: GSRVAT revealed forkhead box p3 (FOXP3) as a susceptibility pathway in 16% of patients with UTC, with an epistasis with DNA mismatch repair. Carriers of germline truncating variants in FOXP3-related susceptibility genes exhibited decreased tumor FOXP3 expression levels, which were associated with a cold tumor microenvironment and significantly reduced overall and progression-free survival following ICI. CONCLUSIONS: Germline variants in a set of FOXP3-related genes confer inherent susceptibility to UTC and contribute to resistance against ICI. The immune-evading trait resulting from these variants and the downregulation of FOXP3 expression introduce a novel avenue for personalized medicine through germline and tumor sequencing.